Peptide comparisons

FOXO4-DRI vs Dasatinib + Quercetin (D+Q)

Same goal — selective elimination of senescent 'zombie' cells — different evidence bases. Dasatinib (a leukemia drug) + Quercetin (a flavonoid) is the small-molecule senolytic combination with multiple Phase 2 human trials in indications like idiopathic pulmonary fibrosis and diabetic kidney disease. FOXO4-DRI is a 47-aa D-retro-inverso peptide with one influential animal paper (Baar 2017 Cell) and zero published human trials. Mechanistically FOXO4-DRI is more elegant — it specifically disrupts FOXO4-p53 binding while leaving healthy cells alone. D+Q hits a broader senolytic target set (BCL-2 family, PI3K/AKT) with predictably broader off-target potential. For patients seeking actual senolytic therapy in 2026, D+Q has the better human evidence base. For the mechanism-curious or for participants in clinical trials, FOXO4-DRI remains the cleaner peptide-class candidate. Neither is established care.

Semax vs Adderall

Different drug classes with different goals. Adderall is a Schedule II amphetamine stimulant with FDA approval for ADHD and narcolepsy — strong, predictable focus and wakefulness, well-characterized side-effect profile (cardiovascular, sleep, appetite, dependence risk). Semax is a 7-aa heptapeptide nasal spray with non-stimulant mechanisms (BDNF/NGF upregulation, dopamine modulation without direct receptor agonism) — prescription-grade in Russia/CIS, research-only in the US. Reported user effects are subtler than Adderall (improved sustained attention, reduced cognitive fatigue) without the crash, appetite suppression, or schedule restriction. Semax is not FDA-approved as ADHD treatment, has thinner human evidence base, and is not a direct substitute. For people seeking non-stimulant focus support, Semax is a research-tier option; for diagnosed ADHD requiring proven treatment, Adderall is FDA-indicated.

Semaglutide vs Tirzepatide

Tirzepatide produces ~50% more weight loss in head-to-head SURMOUNT-5 (20.2% vs 13.7% mean total body weight). Semaglutide has the cardiovascular outcomes trial (SELECT) showing 20% MACE reduction. Tirzepatide has the OSA indication (Zepbound). Both are FDA-approved. Choice depends on indication — CV protection favors semaglutide, maximum weight loss favors tirzepatide.

BPC-157 vs TB-500

BPC-157 has stronger evidence for tendon, ligament, and gut tissue (multiple animal RCTs + small human pilots). TB-500 (a TB-4 fragment) has broader systemic anti-inflammatory action and stronger connective-tissue migration data, but human evidence is thinner. For acute soft-tissue injury, most clinicians stack both. Both are FDA Interim Category 2 as of April 2026.

Cerebrolysin vs P21

Cerebrolysin is a porcine-brain-derived mixture of low-molecular-weight peptides with neurotrophic effects — approved in 50+ countries (not US) for stroke, TBI, and dementia adjunct therapy, with substantial human clinical data including multiple RCTs. P21 is a synthetic 11-aa peptide derived from CNTF (ciliary neurotrophic factor) designed to deliver CNTF's neurogenic action without CNTF's systemic side-effect profile. P21 has compelling animal data (improvements in Alzheimer's models) but no published human trials. For users seeking neurogenic support today, Cerebrolysin has the evidence; P21 is a promising research direction.

Retatrutide vs Tirzepatide

Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) producing ~24% mean total body weight loss in Phase 3 trials — the highest yet documented for any single weight-loss molecule. Tirzepatide (the dual GLP-1/GIP agonist already approved as Mounjaro and Zepbound) tops out around ~22% in long-term studies. Retatrutide's glucagon component drives additional energy expenditure and may avoid the metabolic slowdown seen on GLP-1 monotherapy. Retatrutide remains investigational; Eli Lilly has not yet filed for FDA approval.

Oral semaglutide (Rybelsus) vs Injectable semaglutide (Wegovy / Ozempic)

Same molecule, different delivery, very different bioavailability. Injectable semaglutide (Wegovy 1.0-2.4 mg weekly) achieves ~80% bioavailability and reliably produces 13-15% weight loss. Oral semaglutide (Rybelsus 7-14 mg daily) uses a SNAC absorption-enhancer carrier but still delivers only ~1% bioavailability, meaning the daily oral dose is roughly 30-100x the weekly injection equivalent. Real-world weight loss on Rybelsus is typically 4-8% — about half of injectable. The fasting-and-water-restriction protocol is also onerous. Choose oral for needle aversion or strong pill preference; injectable for maximum efficacy.

GHK-Cu (copper peptides) vs Tretinoin

Different mechanisms, different trade-offs. Tretinoin drives cell turnover — fast surface renewal, visible fine-line reduction in 8-12 weeks, often with significant irritation, dryness, and barrier disruption. GHK-Cu drives dermal-epidermal junction strengthening and collagen synthesis — slower visible results (12-16 weeks) but no irritation, no purging, compatible with sensitive and barrier-compromised skin. For most users with retinoid fatigue, GHK-Cu alone delivers most of the anti-aging benefit. Stack only if you tolerate Tretinoin well and want both turnover (Tret) and structural support (GHK-Cu) — separate by 12+ hours.

CJC-1295 vs Sermorelin

Sermorelin is a 29-aa GHRH analog with a 10-min half-life — produces tight, physiologic GH pulses. CJC-1295 (with DAC) is modified to bind albumin, extending half-life to ~8 days — sustained GH elevation but loses pulsatility. For age-related GH decline, sermorelin is more physiologic. For frequency-of-injection convenience, CJC-1295 wins. Pulsatility likely matters more than total exposure.

Argireline + SNAP-8 topical stack vs Botox (botulinum toxin A)

Same target (SNARE-complex inhibition reducing muscle contraction), very different intensity. Botox is an injected neurotoxin causing complete muscle paralysis lasting 3-4 months — dramatic visible reduction of dynamic wrinkles, requires medical injection, ~$300-700 per treatment area. Argireline + SNAP-8 are topical hexa- and octa-peptides that mimic SNAP-25 fragments to partially inhibit acetylcholine release — ~25-30% of Botox's effect on expression lines, gradual visible reduction over 4-8 weeks of consistent twice-daily use, no injection, ~$30-60 for a serum lasting months. Topicals are not Botox replacements; they are an entry-level alternative for users avoiding injection or treating less pronounced lines. Stack the two peptides at 5%+10% concentrations for additive effect.

KPV vs Thymosin α-1

Different mechanisms despite overlapping immune/inflammation use cases. KPV is a 3-aa α-MSH fragment with localized anti-inflammatory action — strong for IBD, mast-cell, and gut-barrier work. Thymosin α-1 is a 28-aa thymic peptide — broader systemic immune modulation, established in chronic viral infection and immune reconstitution. For gut-specific inflammation, KPV. For systemic immune dysregulation, Tα1.

FOXO4-DRI vs Fisetin

Both target senescent cells. Fisetin is a natural flavonoid (found in strawberries, apples, persimmons) with the broadest natural-product senolytic literature, including Phase 2 trials in older adults. It is cheap, oral, and supplement-grade widely available. FOXO4-DRI is a 47-aa engineered peptide with a clean mechanism story (FOXO4-p53 disruption) but no human trials. Fisetin's senolytic potency is lower per dose than FOXO4-DRI in animal models, but its accessibility, tolerability, and human evidence base put it at the front of the senolytic conversation for general anti-aging users in 2026. FOXO4-DRI remains the more interesting peptide candidate with substantially thinner evidence. For most users curious about senolytic therapy, Fisetin is the rational starting point — not because it's the most potent senolytic, but because it is the most-evidenced and lowest-risk option.